<DOC>
	<DOC>NCT00872950</DOC>
	<brief_summary>The purpose of this study is to determine the effectiveness and adverse effects of 3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS).</brief_summary>
	<brief_title>3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
	<mesh_term>Myasthenic Syndromes, Congenital</mesh_term>
	<mesh_term>3,4-diaminopyridine</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>LEMS diagnosis OR Pre or Post Synaptic CMS diagnosis 18 years or older Females must have negative pregnancy test and be willing to practice an effective form of birth control No prolonged QT syndrome as indicated by baseline EKG Known sensitivity to 3,4DIAMINOPYRIDINE History of seizures and/or severe asthma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>LEMS</keyword>
	<keyword>CMS</keyword>
	<keyword>3,4 DIAMINOPYRIDINE</keyword>
	<keyword>3,4 DAP</keyword>
</DOC>